HDAC1 and cancer: Furthermore, Alectinib showed a dual inhibition effect on both ALK and HDAC1, and therefore, it may have additional therapeutic value in cancer subtypes involving ALK and HDAC1, such as ALK-rearranged and HDAC1-overexpressing tumors.